Initial anti-tumor activity data from ABILITY’s fifth and sixth dose escalation cohort expected in calendar Q3 2023. Commencement of the ABILITY study’s Phase 2 single agent dose expansion portion expected in calendar Q3 2023. Clinical update from the ABILITY study’s Phase 2 single agent portion expected in calendar Q4 2023. Commencement of the ABILITY study’s Phase 2 combination portion expected in calendar Q4 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDNA: